News Conference News ACC 2025 FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints L.A. McKeown April 03, 2025
News Conference News ACC 2024 Vaping Linked to Higher Risk of HFpEF, NIH Data Show L.A. McKeown April 12, 2024
News Conference News ACC 2024 Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It Michael O'Riordan March 27, 2024
News Conference News ACC 2023 IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF L.A. McKeown March 14, 2023
News Conference News ACC 2023 AIMI-HF Misses Mark With Advanced Imaging in Ischemic HFrEF Workup L.A. McKeown March 09, 2023
News Conference News ACC 2023 BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF L.A. McKeown March 06, 2023
News Conference News ACC 2022 DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF L.A. McKeown April 08, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News ACC 2021 Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF Yael L. Maxwell May 16, 2021
News Conference News ACC 2019 New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin Shelley Wood March 26, 2019